Page 2 - Markus Warmuth News Today

10.11.2022 - – Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors – – Progressed VAV1 Molecular Glue Degrader Program into Lead Optimization – BOSTON, Nov. 10, ...

She previously served as SVP, head of business development.

Press release content from Business Wire. The AP news staff was not involved in its creation. Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform March 12, 2021 GMT BOSTON--(BUSINESS WIRE)--Mar 12, 2021-- Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a $95 million Series C financing. The proceed...

RTW Participates in $95 Million Financing Round in Monte Rosa Therapeutics RTW Venture Fund Limited (the "Company"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Monte Rosa Therapeutics, Inc. ("Monte Rosa") on 12 March 2021 of its completion of a $95 million Series C financing round. The Company, alongside other investment vehicles o...

Published: Feb 08, 2021   Silvia Buonamici, Ph.D.,   BOSTON--(BUSINESS WIRE)-- Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the appointments of Owen Wallace, Ph.D., as Chief Scientific Officer and Silvia Buonamici, Ph.D., as Senior Vice President, Drug Discovery Biology, as the company continues to expand its executive leadership team. Drs. Wallace and Buonamici will overse...

01.29.21 -- How To Establish An Effective CRO Partnership   Continuing our Cell & Gene Series, Business of Biotech features Dr. Bobby Gaspar, Orchard Therapeutics CEO, speaking on the challenges his company faces in the production of hematopoietic stem cells to treat neurometabolic disorders, primary immune deficiencies, and blood disorders. Listen now and subscribe so you never miss an episode. Video Josh Brumm, CEO of Dyne Therapeutics, discusses some of th...

01/25/21 Life Science Leader Newsletter